Adding a new facet to STAT5 in CML: multitasking for leukemic cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

1. Identification of Active Phytochemicals to Inhibit Signal Transducer and Activator of Transcription 5A (STAT5A) Dimerization for Prostate Cancer Therapy: AnAnti-cancer agents in medicinal chemistry · 2025
   Article
2. Low Renalase Levels in Newly Diagnosed CML: Dysregulation Sensitive to Modulation by Tyrosine Kinase Inhibitors.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
   Article
3. Dysregulated Signalling Pathways Driving Anticancer Drug Resistance.International journal of molecular sciences · 2023
   Review
4. Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells.BMC cancer · 2022
   Article
5. Potential ApproachesFrontiers in oncology · 2021
   Review
6. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.Journal of experimental & clinical cancer research : CR · 2020
   Article
7. Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology.Oncogene · 2019
   Review
8. PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis.Leukemia · 2014
   Article
9. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.Haematologica · 2014
   Review
10. Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia.Oncoscience · 2014
    Article
11. STAT inhibitors for cancer therapy.Journal of hematology & oncology · 2013
    Review

Corrections and comments

• Comment on
  STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.2012

Authors and funding

3 authors at 3 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as